# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company ...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to ap...
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.14) by 100...
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA ...
Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before s...
CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders. This letter will be sent to the Company's shareho...